EVERSANA adds AI to medical, legal and regulatory reviews

EVERSANA has added another feature to its ORCHESTRATE platform for the commercialisation of life science products – an artificial intelligence-powered toolkit designed to make medical, legal, and regulatory (MLR) review processes more accurate and efficient.

The newly launched EVERSANA ORCHESTRATE MLR can automate 90% of the common tasks in MLR, a complex and often time-consuming and costly review process that companies carry out to make sure their advertising and promotional content is accurate, compliant with regulations, and okay to be published.

It is a critical task to make sure that the content is 100% accurate – otherwise, patient safety could be compromised and companies could be exposed to the risk of hefty fines, litigation risks, and damage to their reputations.

With its new launch, EVERSANA aims to streamline the MLR process, which remains a largely manual effort in most organisations, generally takes weeks to complete, and according to some estimates can cost large companies tens of millions of dollars per year.

Using ORCHESTRATE MLR, teams can automatically identify, extract and manage claims in minutes, avoiding the need to comb through hundreds of marketing materials and cross-reference them with regulatory claims information.

According to EVERSANA – which is pharmaphorum's parent company – annotation and cross-referencing for creative-type documents against claims data can now be completed in just a few clicks.

Users of the system will see all claims identified in the document and what needs to be updated and can make these updates in real-time, resulting in 90% faster content updates and an overall reduction in content reviews by as much as 50%, according to a statement on the launch.

Testing in partnership with several life sciences companies has suggested it can reduce submission errors by 86% and result in cost savings of around 35% for a typical MLR team.

EVERSANA chief executive Jim Lang said ORCHESTRATE MLR is a "game changer" for life sciences companies and will "set a new standard for efficiency, compliance, and quality that is much needed in today's industry."

The software is built on Amazon Bedrock suite of generative AI (GenAI) foundation models and was created by EVERSANA in collaboration with Amazon Web Services (AWS), product engineering specialist Modus Create, and Veeva, a specialist in cloud software for the life sciences industry.

"Generative AI is transforming the life sciences industry by accelerating R&D, improving efficiency in manufacturing, and streamlining the path to commercialisation," said Dan Sheeran, AWS' general manager, healthcare and life sciences.

"The AI moment for life sciences is happening now, and our collaboration with EVERSANA demonstrates how AI technology is delivering solutions that not only solve long-standing industry challenges but also bring better therapies to patients faster."